Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
VIFOR (INTERNATIONAL) AG currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, indicating a very focused point of contact with the patent office. This single pending matter constitutes the entirety of the company's current active prosecution.
The prosecution is taking place in 1 distinct art unit. O DELL, DAVID K is the busiest examiner for the portfolio, with 1 pending office action currently under review. Because the busiest examiner pending count is 1, this individual is the sole official responsible for the company's pending workload. Their specific background in biotechnology and their examination style will be the most critical factors in the portfolio's development.
Practitioners should note that with only 1 pending office action and 1 distinct examiner, the strategy must be precisely aligned with that examiner's expectations. There is no diversity in art units to provide alternative prosecution environments. Success for VIFOR (INTERNATIONAL) AG depends on a successful negotiation with this single examiner within the Biotechnology & Pharmaceuticals art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744642 | CALCIUM OXALATE CRYSTALLIZATION INHIBITORS FOR RENAL DISORDERS | O DELL, DAVID K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18744642 | CALCIUM OXALATE CRYSTALLIZATION INHIBITORS FOR RENAL DISORDERS | O DELL, DAVID K | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18744642 | CALCIUM OXALATE CRYSTALLIZATION INHIBITORS FOR RENAL DISORDERS | O DELL, DAVID K | 1621 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial